Fig. 2.
Effects of As2O3 or cAMP or both on primary leukemia cells from 2 patients with de novo APL.
(A) Morphologic features of primary leukemia cells from patient 1 after 9 days of exposure to the drugs as indicated. Similar morphologic changes were also observed in patient 2. Original magnification × 1000. (B) Expression of CD11b integrin of primary leukemia cells from patient 1 and patient 2 following the indicated treatments. (C) NBT-reducing activity of primary leukemia cells from patient 1 and patient 2 following the indicated treatments.